Conceptual stability-packaging still life with four upright lyophilized vials, cartons, foil pouch and a data logger

A lyophilized peptide’s proposed shelf life needs evidence for the specified material in its proposed packaging. A dry appearance, an intact-looking cake or a familiar vial shape cannot establish how long the product remains within its agreed specification. Before approving a label, ask which study supports the storage statement and whether that study covers the presentation being ordered.

This question arises in bulk-material supply, lyophilized vial OEM and private-label projects. The evidence package should follow the product and intended use, rather than a shelf-life number borrowed from a different product.

Identify the claim that needs evidence

Separate an unopened storage statement from a transport condition or any proposed period after opening. Those claims concern different situations. A material retest period and a finished-product expiry date also need clear definitions in the project documents.

ICH Q1A(R2) describes stability information for new drug substances and products. EMA lists a legal effective date of 1 August 2003. It provides pharmaceutical context for evidence-based storage and dating, not a universal shelf-life rule for every cosmetic or research peptide.

Ask what the supplied report actually covers

  • The identity and form of the material studied.
  • The batch or batches represented in the study.
  • The product-contact container and closure used.
  • The measured quality attributes and their acceptance criteria.
  • The study conditions, observation period and authorized conclusion.

A summary should identify its supporting report. If the conclusion depends on a different package or formulation, ask how that difference has been assessed. The answer may be that more evidence is needed; that should be resolved before artwork or supply terms imply an established shelf life.

Treat packaging as part of the stability question

Proposed changeEvidence questionRecord to review
Different vial or closureDoes the supporting evidence cover the proposed product-contact components?Component specifications and documented assessment
Different fill presentationDoes the conclusion apply to this presentation?Approved presentation and study applicability assessment
Added pouch or secondary packWhat protection is being claimed, and what supports it?Packaging specification and relevant evidence
New distribution routeWhich transport exposure has been assessed?Shipment requirements and excursion review arrangements
Revised storage wordingWho authorized the wording and the dating basis?Approved report conclusion and artwork revision

These are review prompts, not predetermined test requirements. A qualified technical team should decide the work appropriate to the product. A carton redesign that leaves product-contact packaging unchanged may present a different question from replacing the closure; the record should explain the assessment.

Keep release testing separate from stability support

A certificate of analysis reports results for a particular sample or batch under the stated test conditions. It does not automatically establish the product’s future condition throughout a proposed storage period. Keep the release specification, stability conclusion and packaging approval traceable to one another.

Appearance can be one recorded attribute. Ask which other attributes are relevant to the agreed specification and how changes would be detected. For medicinal projects within their scope, ICH Q2(R2) and ICH Q14 provide context for analytical procedures used in release and stability testing.

Cosmetic projects need their own product evidence

FDA’s cosmetic shelf-life information explains that shelf life varies with the product, use and storage, and places responsibility for determining it with the manufacturer. A storage conclusion for a peptide ingredient should therefore not be presented as proof of the shelf life of a complete cosmetic formulation.

When the ingredient is incorporated into another format, ask what evidence addresses that finished presentation. Avoid transferring a supplier’s raw-material claim directly onto a consumer-facing product.

Agree what happens when shipping conditions differ

Put any documented transport requirements into the order. If monitoring is included, define who reviews the record and what happens when an excursion is reported. A data logger supplies observations; the acceptance decision needs an agreed technical basis.

Do not assign a generic storage temperature or allowable excursion duration to all peptides. Request the supported conditions for the specified material and package. If the receiving organization has additional handling requirements, reconcile them with the supplier before shipment.

  • Make the label and delivery documents use the same approved storage wording.
  • Identify the report supporting any retest or expiry statement.
  • Record the package revision linked to that conclusion.
  • Name the party authorized to assess a transport deviation.

Hytanbio’s lyophilized peptide project page describes the relevant supply format. Include packaging and evidence requirements in your enquiry, and use the quotation comparison guide to check which documentation work is priced separately.

Frequently asked questions

Does lyophilization establish a fixed shelf life for every peptide?

No. A proposed storage period needs evidence for the specified material and presentation. The study conclusion should identify the relevant product, package, conditions and measured attributes.

Can a release COA replace stability evidence?

A release COA records specified results for a sample or batch at the time of testing. Supporting a storage period requires evidence relevant to change over time under the proposed conditions.

Can an ingredient's shelf life be used for a finished cosmetic product?

It should not be transferred automatically. Ask for evidence covering the complete formulation and proposed package, and establish who is responsible for the finished product's shelf-life determination.

What temperature should all peptide vials be shipped at?

There is no universal temperature specified by this guide. Request the documented transport conditions for the exact material and package, and agree how any reported excursion will be assessed.

References and scope

  1. EMA: ICH Q1A(R2), Stability testing of new drug substances and drug products.
  2. EMA: ICH Q2(R2), Validation of analytical procedures.
  3. EMA: ICH Q14, Analytical procedure development.
  4. FDA: Shelf Life and Expiration Dating of Cosmetics.
Editorial scope

Prepared by the Hytanbio Technical Editorial Team for B2B project planning. Company-specific information is based on supplied company materials. Project specifications and documentation must be confirmed for the requested product and intended market.